Cryopreserved Plateable RAT Hepatocytes, min of 4 million cells/vial

Cat.No.: CSC-7662W

Species: Rat

Source: Liver

Cell Type: Hepatocyte

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-7662W
Description
Bioarray offers an assortment of various human and non-human hepatic derived cells. These include Hepatocytes, Total Liver Cell Population (TLC), Stellates, Progenitors and Intra-hepatic biliary epithelial cells. We offer these as cryopreserved cells for convenience. Cryopreserved cells are suitable for a variety of assays including induction, toxicity, drug metabolism and systems biology. Both adherent and suspension cells are available. Custom configurations are available upon request.
Species
Rat
Source
Liver
Cell Type
Hepatocyte
Disease
Normal
Storage and Shipping
Ship in dry ice and store in liquid nitrogen
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Cryopreserved Plateable Rat Hepatocytes represent the definitive in vitro model for evaluating hepatic metabolism, drug-drug interactions (DDI), and long-term cytotoxicity. Unlike suspension cells, our plateable hepatocytes are specifically optimized to re-establish a confluent, polarized monolayer in culture, mimicking the complex microenvironment of the liver parenchyma with high physiological fidelity.

  • Long-Term Metabolic Stability: These hepatocytes maintain high levels of Phase I (CYP450) and Phase II (UGT, SULT) enzyme activities for up to 5-7 days in culture. This extended window is critical for identifying low-clearance compounds and metabolites that shorter assays might miss.
  • Biliary Excretion & Transporter Activity: Our proprietary cryopreservation and recovery protocols ensure the preservation of key uptake (OATP, NTCP) and efflux (MDR1, MRP2) transporters. This makes them an ideal platform for studying hepatobiliary transport and cholestatic potential.
  • Superior Attachment & Morphology: Validated for high attachment efficiency (>80%), these cells form robust bile canaliculi-like structures and maintain clear cell-cell boundaries, ensuring reproducible data across multiple plates and lots.
  • Species-Specific Extrapolation: Utilizing high-quality Sprague-Dawley or Wistar strains, these cells provide the essential benchmark for in vitro to in vivo extrapolation (IVIVE), allowing for direct comparison with preclinical rat safety data.

By utilizing our cryopreserved plateable hepatocytes, you eliminate the variability and scheduling constraints of fresh tissue isolation while gaining a standardized, ready-to-use system for high-confidence toxicity screening.

Differences in Thyroxine (T4) Metabolism Following In Vitro Exposure of Wistar Rat and Human Hepatocytes to CAR/PXR Activators

The species differences in thyroxine (T4) metabolism regulation by CAR/PXR activators were investigated using cryopreserved primary Wistar rat hepatocytes (PRH) and human hepatocytes (PHH) in 2D-sandwich over a 7-day treatment period.

Daily exposure of PRH to phenobarbital, 5-Pregnen-3β-ol-20-one-16α‑carbonitrile (PCN) or dexamethasone increased T4 clearance over the last 24 h exposure (up to 60 %, 79 % and 67 % over control, respectively) and secretion of T4-glucuronide (T4-G; up to 463, 661 and 545 pmol/106 cells over control, respectively). Effects were concentration-dependent for phenobarbital and PCN and highest at the lowest concentration for dexamethasone, while rifampicin barely affected T4 clearance and T4-G secretion. None of the compounds, at any tested concentration, affected these parameters in PHH. Additionally, mRNA expression data were consistent with the species-specific and concentration-dependent regulation of phase I Cyp/CYP, phase II Ugt/UGT and phase III Mrp2/MRP2 pathways occurring in rat and human liver following CAR/PXR activation. T4-UGT relative activity increased in PRH only, specifically by PCN, dexamethasone and phenobarbital. The comparison of PRH and PHH responses to compounds represents an important step towards using in vitro methods to reduce animal testing.

Primary rat and human hepatocyte 2Dsw cultures differ in their response to CAR/PXR activators in terms of thyroxine metabolism.

Fig. 1. Effect of PCN on (A) induction of T4 uptake, metabolism and excretion pathways, (B) T4 clearance and (C) T4 metabolite formation in 2Dsw cultured primary Wistar rat hepatocytes (PRH) and primary human hepatocytes (PHH) (Baze, Audrey, et al., 2025).

Comparison of relative CYP and T4-UGT activities in primary rat and human hepatocyte 2Dsw cultures exposed to CAR/PXR activators.

Fig. 2. Effect of reference inducers on CYP2B, CYP3A and T4-UGT activities after 7 days of daily exposure of 2Dsw cultured primary Wistar rat hepatocytes and primary human hepatocytes to CITCO, DEX, PCN, RIF or PB and following incubation with substrates in large excess (100 μM Bupropion for CYP2B, 3 μM Midazolam for CYP3A or 50 μM T4 for T4-UGT activities) (Baze, Audrey, et al., 2025).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products